礼来公司新产品研究开发概况
2001年礼来公司尽管遭遇到通用名药物的竞争，使其 Prozac(fluoxetine)的销售损失较大，但该公司的新产品上市是制药行业中最多的。ayn, http://www.100md.com
该公司过去投产的 Zyprexa 和 Xigris 的销售增长将加快该公司的利润增长速度。到今年末，预计礼来公司又将有4种新药投入生产，即：勃起机能障碍用药 Cialis、骨质疏松用药 Fortero、atomoxetine和 duloxetine。估计从2003年开始，其收入每年增长7-9亿美元。ayn, http://www.100md.com
礼来公司新药研究进展药品名称ayn, http://www.100md.com
适应症ayn, http://www.100md.com
研究进展ayn, http://www.100md.com
上市时间ayn, http://www.100md.com
Xigris(rhAPC)ayn, http://www.100md.com
脓毒症ayn, http://www.100md.com
已获得批准ayn, http://www.100md.com
Cialis(IC351)ayn, http://www.100md.com
勃起机能障碍ayn, http://www.100md.com
已提交上市申请ayn, http://www.100md.com
2002ayn, http://www.100md.com
LY-333531ayn, http://www.100md.com
糖尿病合并症ayn, http://www.100md.com
Ⅲ期临床试验阶段ayn, http://www.100md.com
2004ayn, http://www.100md.com
Forteo(rhPTH1-34)ayn, http://www.100md.com
骨质疏松症ayn, http://www.100md.com
已提交上市申请ayn, http://www.100md.com
2002ayn, http://www.100md.com
Resiquimodayn, http://www.100md.com
抗病毒ayn, http://www.100md.com
Ⅲ期临床试验阶段ayn, http://www.100md.com
2005ayn, http://www.100md.com
Atomoxetineayn, http://www.100md.com
注意力缺陷障碍ayn, http://www.100md.com
已提交上市申请ayn, http://www.100md.com
2002ayn, http://www.100md.com
Alimata(MTA)ayn, http://www.100md.com
实体瘤ayn, http://www.100md.com
Ⅲ期临床试验阶段ayn, http://www.100md.com
2003ayn, http://www.100md.com
Arzoxifeneayn, http://www.100md.com
乳腺肿瘤ayn, http://www.100md.com
Ⅲ期临床试验阶段ayn, http://www.100md.com
2004ayn, http://www.100md.com
MgluR2ayn, http://www.100md.com
焦虑症ayn, http://www.100md.com
Ⅱ期临床试验阶段ayn, http://www.100md.com
2005/2006ayn, http://www.100md.com
GLP-1ayn, http://www.100md.com
Ⅱ型糖尿病ayn, http://www.100md.com
Ⅱ期临床试验阶段ayn, http://www.100md.com
2005/2006ayn, http://www.100md.com
Sivelestatayn, http://www.100md.com
急性肺损伤/急性呼吸窘迫综合症ayn, http://www.100md.com
Ⅱ期临床试验阶段ayn, http://www.100md.com
2005/2006ayn, http://www.100md.com
LY-335979ayn, http://www.100md.com
乳腺癌、白血病ayn, http://www.100md.com
ⅡB期临床试验阶段ayn, http://www.100md.com
2004
该公司过去投产的 Zyprexa 和 Xigris 的销售增长将加快该公司的利润增长速度。到今年末，预计礼来公司又将有4种新药投入生产，即：勃起机能障碍用药 Cialis、骨质疏松用药 Fortero、atomoxetine和 duloxetine。估计从2003年开始，其收入每年增长7-9亿美元。ayn, http://www.100md.com
礼来公司新药研究进展药品名称ayn, http://www.100md.com
适应症ayn, http://www.100md.com
研究进展ayn, http://www.100md.com
上市时间ayn, http://www.100md.com
Xigris(rhAPC)ayn, http://www.100md.com
脓毒症ayn, http://www.100md.com
已获得批准ayn, http://www.100md.com
Cialis(IC351)ayn, http://www.100md.com
勃起机能障碍ayn, http://www.100md.com
已提交上市申请ayn, http://www.100md.com
2002ayn, http://www.100md.com
LY-333531ayn, http://www.100md.com
糖尿病合并症ayn, http://www.100md.com
Ⅲ期临床试验阶段ayn, http://www.100md.com
2004ayn, http://www.100md.com
Forteo(rhPTH1-34)ayn, http://www.100md.com
骨质疏松症ayn, http://www.100md.com
已提交上市申请ayn, http://www.100md.com
2002ayn, http://www.100md.com
Resiquimodayn, http://www.100md.com
抗病毒ayn, http://www.100md.com
Ⅲ期临床试验阶段ayn, http://www.100md.com
2005ayn, http://www.100md.com
Atomoxetineayn, http://www.100md.com
注意力缺陷障碍ayn, http://www.100md.com
已提交上市申请ayn, http://www.100md.com
2002ayn, http://www.100md.com
Alimata(MTA)ayn, http://www.100md.com
实体瘤ayn, http://www.100md.com
Ⅲ期临床试验阶段ayn, http://www.100md.com
2003ayn, http://www.100md.com
Arzoxifeneayn, http://www.100md.com
乳腺肿瘤ayn, http://www.100md.com
Ⅲ期临床试验阶段ayn, http://www.100md.com
2004ayn, http://www.100md.com
MgluR2ayn, http://www.100md.com
焦虑症ayn, http://www.100md.com
Ⅱ期临床试验阶段ayn, http://www.100md.com
2005/2006ayn, http://www.100md.com
GLP-1ayn, http://www.100md.com
Ⅱ型糖尿病ayn, http://www.100md.com
Ⅱ期临床试验阶段ayn, http://www.100md.com
2005/2006ayn, http://www.100md.com
Sivelestatayn, http://www.100md.com
急性肺损伤/急性呼吸窘迫综合症ayn, http://www.100md.com
Ⅱ期临床试验阶段ayn, http://www.100md.com
2005/2006ayn, http://www.100md.com
LY-335979ayn, http://www.100md.com
乳腺癌、白血病ayn, http://www.100md.com
ⅡB期临床试验阶段ayn, http://www.100md.com
2004